On November 18, 2024, Allarity Therapeutics, Inc. announced significant progress in its ongoing Phase 2 clinical trial for stenoparib, an advanced ovarian cancer treatment. The company reported that two patients have been on the treatment for over 14 months, indicating a potential for stenoparib as a viable option for patients with advanced ovarian cancer who have undergone multiple prior therapies. Alongside the clinical trial update, Allarity also revealed a strengthened financial position with a cash balance of $18.5 million, which is expected to support the initiation of a follow-up FDA registrational trial for stenoparib. Additionally, the company's Allarity Medical Laboratory has expanded into providing revenue-generating services to external biotech clients, leveraging its advanced gene expression and diagnostic capabilities. This expansion into service...Show More

On November 18, 2024, Allarity Therapeutics, Inc. announced significant progress in its ongoing Phase 2 clinical trial for stenoparib, an advanced ovarian cancer treatment. The company reported that two patients have been on the treatment for over 14 months, indicating a potential for stenoparib as a viable option for patients with advanced ovarian cancer who have undergone multiple prior therapies. Alongside the clinical trial update, Allarity also revealed a strengthened financial position with a cash balance of $18.5 million, which is expected to support the initiation of a follow-up FDA registrational trial for stenoparib. Additionally, the company's Allarity Medical Laboratory has expanded into providing revenue-generating services to external biotech clients, leveraging its advanced gene expression and diagnostic capabilities. This expansion into service agreements is anticipated to reduce Allarity's laboratory costs and further establish its proprietary Drug Response Predictor (DRP®) platform within the oncology field. The company's CEO, Thomas Jensen, expressed optimism about the clinical benefits observed in the trial and the company's ability to accelerate stenoparib's development towards FDA approval.